Fig. 5
Tumor-derived GCSF inhibits cDC1 development. a ISH for Csf3 on end-stage PyMT-B6 and KPC tumor tissue and tumor-free mammary or pancreas tissue; n = 3 per group. Scale bar 25 μm. b Human patient BC and PDAC tumor tissue stained for GCSF. BC graded for low, medium, and high staining per tumor cell; BC, n = 106; PDAC, n = 5. Scale bar 10 μm. c Number of BM pre-DCs, CD24+ cDC1s, and immature granulocytes and blood pre-DCs from mice bearing end-stage orthotopic PyMT-B6 or PyMT-B6 GCSFKO mammary tumors relative to tumor-free controls, n = 6/group. End stage for each model is defined in the Methods. Error bars represent mean +/− s.e.m.; *p < 0.05, **p < 0.01 by unpaired two-sided Student’s t test
